Related Experiment Videos
Intensive short course chemotherapy for tuberculous meningitis
R F Jacobs1, P Sunakorn, T Chotpitayasunonah
1Department of Pediatrics, Arkansas Children's Hospital, Little Rock 72202.
Insights
A 6-month treatment for tuberculous meningitis in children using pyrazinamide (PZA) is more effective than longer regimens without PZA. This short-course chemotherapy reduces mortality and long-term complications in pediatric patients.
Area of Science:
- Pediatric Infectious Diseases
- Tuberculosis Research
- Clinical Pharmacology
Background:
- Tuberculous meningitis (TBM) poses a significant threat to children, with high mortality and sequelae rates.
- Advanced disease stages at diagnosis correlate with poor outcomes in pediatric TBM.
- Optimal treatment duration and drug combinations for pediatric TBM remain areas of active investigation.
Purpose of the Study:
- To evaluate the efficacy of different treatment durations and drug regimens for pediatric tuberculous meningitis.
- To determine if a shorter chemotherapy course incorporating pyrazinamide (PZA) improves outcomes compared to longer courses without PZA.
- To assess the impact of disease severity at presentation on mortality and sequelae in children with TBM.
Main Methods:
- A nonrandomized, open clinical investigation involving 53 children with Stages I, II, and III tuberculous meningitis.
- Administration of various combinations of standard antitubercular drugs: isoniazid, rifampin, pyrazinamide, streptomycin, and ethambutol.
- Comparison of three treatment durations: 12 months, 9 months, and a 6-month regimen including PZA.
Main Results:
- Severe TBM at presentation was significantly associated with increased early mortality (P < 0.05).
- The 6-month intensive short-course chemotherapy regimen with PZA demonstrated superior efficacy in preventing negative outcomes and sequelae (P < 0.05).
- This shorter regimen was more effective than longer therapies (9 or 12 months) that did not include PZA, irrespective of initial disease stage.
Conclusions:
- A 6-month treatment regimen containing pyrazinamide (PZA) is an effective strategy for treating pediatric tuberculous meningitis.
- Intensive short-course chemotherapy with PZA offers a promising approach to reduce mortality and sequelae in children with TBM.
- Early diagnosis and treatment initiation are crucial, but optimized chemotherapy regimens can significantly improve patient outcomes.
Abstract:
This nonrandomized, open clinical investigation of tuberculous meningitis evaluated 53 children with Stage I (n = 8), Stage II (n = 29) and Stage III (n = 16) disease. The overall mortality was 20.8% (11 of 53) with a rate of sequelae of 35.7% (15 of 42) in survivors reflecting the advanced stages of children at diagnosis. Various combinations of standard antituberculous drugs including isoniazid, rifampin, pyrazinamide, streptomycin and ethambutol were given. Three treatment durations used during various time periods were evaluated: 12, 9 and 6 months with only the 6-month regimen receiving pyrazinamide (PZA). This prospective evaluation demonstrated that: (1) severe disease at presentation is highly associated with early mortality (P less than 0.05), regardless of drug regimen; and (2) intensive short course chemotherapy (6 months) with PZA, regardless of stage of disease at presentation, is more efficacious than longer course therapy (9 or 12 months) without PZA in preventing total negative outcomes and sequelae (P less than 0.05). This study demonstrates that a 6-month regimen containing PZA can be used in treating children with tuberculous meningitis.